Categories: News

Bitget Stock Futures Surpass $1 Billion in Cumulative Trading Volume

VICTORIA, Seychelles, Nov. 6, 2025 /PRNewswire/ — Bitget, the world’s largest Universal Exchange (UEX), has seen its US Stock Futures trading volume rocket past $1 billion, doubling its momentum in just two weeks. The milestone reflects strong market adoption of Bitget’s stock-linked derivatives and the growing demand for tokenized exposure to traditional financial assets.

- Advertisement -

The surge coincides with a historic rally in US equities driven by artificial intelligence advancements and a robust Q3 earnings season. Traders on Bitget have shown particular interest in AI and technology leaders, with Tesla (TSLA), Strategy (MSTR), Apple (APPL) emerging as the top three most traded assets, recording cumulative volumes of $380 million, $262 million, and $87 million, respectively.

- Advertisement -

Launched back in September, Bitget’s USDT-margined perpetual futures allow traders to access derivatives on 25 leading US stocks, including Apple, Amazon, Meta, and NVIDIA, with up to 25x leverage and competitive fees at or below 0.06%. The listings offer exposure to some of the world’s most influential companies across technology, finance, consumer goods, and industrial sectors, all within a crypto-native trading environment.

- Advertisement -

Building on this success, Bitget expanded its stock-linked product suite with the addition of NFLXUSDT, FUTUUSDT, JDUSDT, RDDTUSDT, and QQQUSDT stock index perpetual futures, further strengthening its portfolio of Real World Asset (RWA) products for global traders.

- Advertisement -

“Crossing the $1 billion mark in such a short time shows how fast traders are embracing stock futures as part of a unified digital trading experience,” said Gracy Chen, CEO of Bitget. “It’s a signal that the line between traditional markets and digital assets is disappearing, and our Universal Exchange model is where that convergence is happening first.”

- Advertisement -

The introduction of Stock Futures complements Bitget’s broader UEX framework, which integrates centralized, decentralized, and tokenized markets within a single platform. This approach allows users to express equity views, hedge positions, and deploy strategies within a capital-efficient, 24/7 derivatives infrastructure that retains full crypto-native execution and transparency.

- Advertisement -

As tokenization and around-the-clock trading models gain global traction, Bitget’s rapid momentum underscores its leadership in shaping the future of multi-asset trading. One where stocks, digital assets, and on-chain instruments coexist seamlessly.

- Advertisement -

About Bitget

- Advertisement -

Established in 2018, Bitget is the world’s largest Universal Exchange (UEX), serving over 120 million users with access to millions of crypto tokens, tokenized stocks, ETFs, and other real-world assets on a single platform. The ecosystem is committed to helping users trade smarter with its AI-powered trading tools, interoperability across tokens on Bitcoin, Ethereum, Solana, and BNB Chain, and wider access to real-world assets. On the decentralized side, Bitget Wallet runs as the leading non-custodial crypto wallet supporting 130+ blockchains and millions of tokens. It offers multi-chain trading, staking, payments, and direct access to 20,000+ DApps, with advanced swaps and market insights built-in the platform.

- Advertisement -

Bitget is driving crypto adoption through strategic partnerships, such as its role as the Official Crypto Partner of the World’s Top Football League, LALIGA, in EASTERN, SEA and LATAM markets. Aligned with its global impact strategy, Bitget has joined hands with UNICEF to support blockchain education for 1.1 million people by 2027. In the world of motorsports, Bitget is the exclusive cryptocurrency exchange partner of MotoGP™, one of the world’s most thrilling championships.

- Advertisement -

For more information, visit: Website | Twitter | Telegram | LinkedIn | Discord | Bitget Wallet

- Advertisement -


Risk Warning:

Digital asset prices are subject to fluctuation and may experience significant volatility. Investors are advised to only allocate funds they can afford to lose. The value of any investment may be impacted, and there is a possibility that financial objectives may not be met, nor the principal investment recovered. Independent financial advice should always be sought, and personal financial experience and standing carefully considered. Past performance is not a reliable indicator of future results. Bitget accepts no liability for any potential losses incurred. Nothing contained herein should be construed as financial advice. For further information, please refer to our Terms of Use.

- Advertisement -

Photo – https://mma.prnewswire.com/media/2815386/Bitget_Stock_Futures_Surpass__1_Billion_Cumulative_Trading_Volume.jpg

- Advertisement -

View original content:https://www.prnewswire.co.uk/news-releases/bitget-stock-futures-surpass-1-billion-in-cumulative-trading-volume-302606686.html

- Advertisement -

Recent Posts

Crypto News: AlphaPepe Presale Records Surge in Whale Accumulation As Bitcoin Price Prediction Eyes $180,000

MONACO, May 16, 2026 (GLOBE NEWSWIRE) -- Crypto news is turning toward AlphaPepe after the…

2 hours ago

Crypto Market News: AlphaPepe Finalizes Tier-1 Exchange Shortlist as XRP Price Prediction Targets $5.00

MONACO, May 16, 2026 (GLOBE NEWSWIRE) -- Crypto market news is turning toward AlphaPepe after…

2 hours ago

Qoder Version 1.0 Released: Full Automation of Code Generation, Verification & Delivery

SINGAPORE, May 16, 2026 (GLOBE NEWSWIRE) -- Qoder officially releases version 1.0, upgrading from an…

2 hours ago

Ipsen presents first-in-class late-breaking Phase II corabotase data in glabellar lines showing sustained duration of effect reinforced by consistently high patient satisfaction

Patients treated with corabotase showed a rapid onset of action of 0.84 days and peak effect statistically superior to placeboAt Week 24, 60.8% of patients treated with corabotase experienced clinically…

2 hours ago

ImPact Biotech Presents Updated Data from Phase 3 ENLIGHTED Trial of Padeliporfin VTP in LG-UTUC at AUA 2026

– Complete response (CR) observed in 70% (50/72) of evaluable patients with low-grade upper tract…

2 hours ago

Allarity Therapeutics Reports First Quarter 2026 Results and Continued Stenoparib Development in Multiple Cancers

- Stenoparib clinical development continues in relapsed small cell lung cancer and, under FDA Fast…

2 hours ago